ライフサイエンスコーパス: lipid mediator

1 kotriene B4 (LTB4), a potent proinflammatory lipid mediator.

2 e to inappropriate synthesis of proresolving lipid mediators.

3 LTB4, LTC4, LTD4, and LTE4) are inflammatory lipid mediators.

4 on, hydrolysis and oxidation of these potent lipid mediators.

5 oxygenated fatty acids, including well-known lipid mediators.

6 is represents a new biosynthetic pathway for lipid mediators.

7 trates that these enzymes use for generating lipid mediators.

8 munity and the presence of many cytokine and lipid mediators.

9 st powerful eosinophil chemoattractant among lipid mediators.

10 er and acting as substrates for synthesis of lipid mediators.

11 the biosynthesis of specialized proresolving lipid mediators.

12 o generate precursors of potent inflammatory lipid mediators.

13 ratio of proresolving versus proinflammatory lipid mediators.

14 ammatory responses through the production of lipid mediators.

15 re obtained with candidate pollen-associated lipid mediators.

16 d by a switch from inflammatory to resolving lipid mediators.

17 g cytokines, chemokines, growth factors, and lipid mediators.

18 The proresolving lipid mediator, 15-epi lipoxin A4 (15-epi LXA4), plays a

19 roup IVA (cPLA2alpha) activation, are potent lipid mediators also attributed to acute and chronic inf

20 ses including allergy is their production of lipid mediators, among which only omega-6 (omega-6) arac

21 rted IEC expulsion that was coordinated with lipid mediator and cytokine production and lytic IEC dea

22 ine kinase (SphK) is the major source of the lipid mediator and G protein-coupled receptor agonist sp

23 Alterations in the lipid mediators and an imbalance in the metabolism of ce

24 rate endogenous biosynthesis of proresolving lipid mediators and expression of receptors for RvD1 in

25 spite their recognition as anti-inflammatory lipid mediators and regulators of ion channels, little i

26 fatty acid epoxides as new mast cell-derived lipid mediators and show that they are produced by PAF-A

27 -MS/MS methods that collectively quantify 26 lipid mediators and their metabolites, with on-column li

28 s have investigated specialized proresolving lipid mediators and their relation to other lipid mediat

29 transport proteins may alter the traffic of lipid mediators and thus affect their signaling and enzy

30 Excessive adipocyte lipolysis generates lipid mediators and triggers inflammation in adipose tis

31 synthesis of the proinflammatory leukotriene lipid mediators and, together with 15-LOX, is also requi

32 ecrements in select inflammatory peptide and lipid mediators, and more rapid resolution of airway hyp

33 a bioactive process, mediated by specialized lipid mediators, and that normal homeostasis is maintain

34 , the production of specialized proresolving lipid mediators, and their importance for mesenchymal st

35 animals and the so-called pollen-associated lipid mediators are codelivered with the allergens and c

36 alyses of polyunsaturated fatty acid-derived lipid mediators are required to determine possible diver

37 eing associated with alteration of bioactive lipid mediators as assessed by mass spectrometry.

38 excretory/secretory products but few related lipid mediators as established by metabololipidomic anal

39 PH domain also binds to phosphatidic acid, a lipid mediator associated with microneme exocytosis.

40 In this context, we discuss lipid mediators associated with the maintenance of healt

41 ism of arachidonic acid results in bioactive lipid mediators beyond prostaglandins that could signifi

42 ies of enzymes and receptors responsible for lipid mediator biosynthesis and function.

43 onooxygenases are believed to participate in lipid mediator biosynthesis and/or their local inactivat

44 that do not express 15-LOX, thus redirecting lipid mediator biosynthesis to the production of proreso

45 portant enzymes for specialized proresolving lipid mediator biosynthesis, resulted in a loss of thera

46 Here we report a novel class of lipid mediators biosynthesized in human retinal pigment

47 and growth factors using an xMAP method, and lipid mediators by liquid chromatography-tandem mass spe

48 Biosynthesis of proresolving lipid mediators by vascular cells and tissues.

49 ted in part by long-chain fatty acid-derived lipid mediators called specialized proresolving mediator

50 e an active process involving a new genus of lipid mediators, called "specialized proresolving lipid

51 This lipid mediator can induce the cardinal signs of inflamma

52 h many soluble factors such as cytokines and lipid mediators can influence ILC2, direct interaction o

53 that production of specialized proresolving lipid mediators contribute to improved mesenchymal strom

54 hat stimulating resolution with proresolving lipid mediators could be a novel approach to treating ch

55 mation of anti-inflammatory and proresolving lipid mediators could underlie beneficial effects attrib

56 oxin A4 (LXA4), a specialized, proresolution lipid mediator, could increase neutrophil phagocytic act

57 Resolvins, a class of lipid mediators, counteract this effect, representing an

58 Both lipid mediators derive from the same pathway, in which a

59 europrotectin-1 (NPD1), an anti-inflammatory lipid mediator derived from omega-3 polyunsaturated fatt

60 Resolvin E1 (RvE1) is an endogenous lipid mediator derived from the omega-3 polyunsaturated

61 Lipid mediators derived from 5-lipoxygenase (5-LO) metab

62 Lipid mediators derived from adipose tissue have been im

63 ng prostaglandins (PG) and leukotrienes, are lipid mediators derived from arachidonic acid.

64 GD2) and cysteinyl leukotrienes (cysLTs) are lipid mediators derived from mast cells, which activate

65 al in this signalling process is an array of lipid mediators derived from polyunsaturated fatty acids

66 Recent evidence suggests that specialized lipid mediators derived from polyunsaturated fatty acids

67 lvins are antiinflammatory and pro-resolving lipid mediators derived from the omega-3 polyunsaturated

68 Bioactive lipid mediators, derived from membrane lipid precursors,

69 imbalance between inflammatory and resolving lipid mediators during atheroprogression.

70 endon explants.Alterations in the profile of lipid mediators during sub-acute injury included low PGE

71 ysis revealed that various anti-inflammatory lipid mediators (e.g., docosahexaenoic acid) were increa

72 and post-treatment plasma were analyzed for lipid mediators (eg, eicosanoids and endocannabinoids) a

73 The sEH degrades natural analgesic lipid mediators, epoxy fatty acids (EpFAs), therefore it

74 s sphingosine-1-phosphate (S1P), a bioactive lipid mediator essential for inflammation.

75 These lipid mediators exert anti-inflammatory and pro-resolvin

76 Sphingosine 1-phosphate (S1P) is a lipid mediator formed by the metabolism of sphingomyelin

77 lectively termed cysteinyl LTs (cysLTs), are lipid mediators formed by the 5-lipoxygenase (5-LO) path

78 Leukotrienes (LTs) are proinflammatory lipid mediators formed from arachidonic acid in a 2-step

79 new method for extracting RNA, protein, and lipid mediators from a single tissue specimen.

80 clearance via PGDH or the class switching of lipid mediators from the prostaglandin to the lipoxin ax

81 Lysophosphatidic acid (LPA), a bioactive lipid mediator generated by the enzymatic activity of ex

82 Resolvins are lipid mediators generated by leukocytes during the resol

83 ing D and E series resolvins, are endogenous lipid mediators generated during the resolution phase of

84 immune responses, induction of autophagy and lipid mediator generation.

85 ng the biomimetic properties of proresolving lipid mediators has not been demonstrated.

86 Newly identified lipid mediators have been recognized as key players duri

87 Specialized proresolving lipid mediators have emerged as powerful modulators of i

88 Lipid mediators have significant roles in many disease p

89 Lipid mediators, highly bioactive compounds synthesized

90 , and lipoxins) with respect to inflammatory lipid mediators (i.e., leukotriene B4 and PGs) in omenta

91 Therefore, we hypothesized that lesional lipid mediator imbalance favors atheroprogression.

92 hingosine 1-phosphate (S1P) is a blood-borne lipid mediator implicated in the regulation of vascular

93 a potent anti-inflammatory and proresolution lipid mediator in several animal models of inflammation,

94 into the as yet unrevealed action of PFOS on lipid mediators in affecting testicular functions.

95 Profiling lipid mediators in biopsies and suction blister fluid ca

96 ings support a unique profile of specialized lipid mediators in bone marrow that contribute to a feed

97 fatty acids for use as energy substrates or lipid mediators in cellular processes.

98 approaches can be used for discovery of new lipid mediators in complex biologic samples.

99 of literature has identified roles for these lipid mediators in distinct nuclear processes.

100 the idea of a role of these key enzymes and lipid mediators in host survival during anthrax disease.

101 ofiling strategies to quantitatively measure lipid mediators in human plasma.

102 Prostaglandins (PGs) are powerful lipid mediators in many physiological and pathophysiolog

103 tored endogenous biosynthesis of n-3-derived lipid mediators in obesity while attenuating adipose tis

104 Specialized proresolving lipid mediators in patients with coronary artery disease

105 that contribute to the modulatory actions of lipid mediators in peripheral nociceptive signaling.

106 bility to produce cytokines, chemokines, and lipid mediators in response to subsequent TLR stimulatio

107 Their presence as the dominant lipid mediators in spontaneous labor at term portends a

108 poxygenase- and lipoxygenase-pathway-derived lipid mediators in spontaneous labor with remarkable pro

109 f platelet activating factor (PAF), a potent lipid mediator, in human PMNs.

110 Analgesic lipid mediators include endogenous agonists of cannabino

111 Proinflammatory lipid mediators including prostaglandin E2 (PGE2) contri

112 PURPOSE OF REVIEW: Lipid mediators including the lysophospholipids, sphingo

113 rocess, governed by specialized proresolving lipid mediators, including lipoxins, resolvins, maresins

114 nd counter-regulated inflammation-initiating lipid mediators, including prostaglandins.

115 to calculate scores for distinct families of lipid mediators, including resolvins, lipoxins, prostagl

116 These novel small lipid mediators, including the resolvins, protectins and

117 y, we report that cPLA(2) and its metabolite lipid mediators induced autophagy in the RAW246.7 macrop

118 cPLA(2) and lipid mediator-induced autophagy is ATG5 dependent.

119 Lipid mediators influence immunity in myriad ways.

120 lipidomics approaches to identify bioactive lipid mediators influencing host inflammation, viral rep

121 PGE2 is a potent lipid mediator involved in maintaining homeostasis but a

122 ophosphatidic acid (LPA) is an extracellular lipid mediator involved in many physiological functions

123 Cysteinyl leukotrienes (CysLTs) are potent lipid mediators involved in bronchoconstriction, mucus s

124 ukotrienes, which are potent proinflammatory lipid mediators involved in chronic inflammatory disease

125 and giving rise to the generation of diverse lipid mediators involved in inflammatory conditions.

126 These findings demonstrate the diversity of lipid mediators involved in maintaining tissue homeostas

127 ebrafish and discovered that prostaglandins, lipid mediators involved in many physiological functions

128 upplementation with specialized proresolving lipid mediators is an important therapeutic strategy in

129 Cytokines and lipid mediators known as eicosanoids play key roles in r

130 PUFA) and the main precursor to the class of lipid mediators known as eicosanoids.

131 Local generation of proresolving lipid mediators (LC-MS/MS) and expression of RvD recepto

132 cytokines, reactive oxygen species, and the lipid mediator leukotriene B(4) (LTB(4)).

133 IL-6 secretion and production of the lipid mediator leukotriene C(4) were unaffected.

134 talyzes the formation of the proinflammatory lipid mediator leukotriene C4 (LTC4).

135 ve found that levels of the pro-inflammatory lipid mediators leukotriene B4 and prostaglandin E2 are

136 months revealed an expansion of inflammatory lipid mediators, Leukotriene B4 and Prostaglandin E2, an

137 ariate modeling, no changes were observed in lipid mediator levels, whereas global structural lipids

138 lated by diacylglycerol kinases (DGKs), is a lipid mediator linked to key biologic functions.

139 proresolving lipid mediator lipidomics and/or protein expression, and

140 C10 promotes the formation of the resolving lipid mediator lipoxin B4, likely by interfering with AA

141 formyl peptide receptor 2 (ALX/FPR2) by the lipid mediators lipoxin A4 and resolvin D1 (RvD1) promot

142 uction of anti-inflammatory and proresolving lipid mediator, lipoxin A4 (LXA4).

143 Here we carried out lipid mediator (LM) metabololipidomics profiling distinc

144 Herein, we studied bioactive lipid mediator (LM) profiles of tendon-derived stromal c

145 We profiled exudate lipid mediators (LM) via metabololipidomics, CO reduced

146 esolution processes and associated bioactive lipid mediators (LMs) mechanistically contribute to this

147 ), potent anti-inflammatory and proresolving lipid mediators (LMs), and their ability to regulate mon

148 ury in mice in part through the proresolving lipid mediator LXA4, and LXA4 itself should be considere

149 ENPP2) is the main source of the lipid mediator lysophosphatidic acid (LPA) in biological

150 Here, we report a key role for the lipid mediator lysophosphatidic acid (LPA) in decidualiz

151 The lipid mediator lysophosphatidic acid (LPA) signals via s

152 reted lysophospholipase D that generates the lipid mediator lysophosphatidic acid (LPA), playing a ke

153 ng, and thrombotic diseases by producing the lipid mediator lysophosphatidic acid (LPA).

154 phospholipase D that generates the bioactive lipid mediator lysophosphatidic acid (LPA).

155 Autotaxin (ATX) generates the lipid mediator lysophosphatidic acid (LPA).

156 a transfer experiments show that the soluble lipid mediator lysophosphatidylcholine (LPC) is released

157 ges and secretion of the resistance-inducing lipid mediator, lysophosphatidylcholine(24:1).

158 f proinflammatory cytokines, chemokines, and lipid mediators, mainly PGE(2) with induction of cycloox

159 the effects of docosahexaenoic acid-derived lipid mediator maresin 1 (MaR1) in dextran sulfate sodiu

160 Peptides and lipid mediators may target one or both of these calcium

161 Mass spectrometry-based lipid mediator metabololipidomics demonstrated that DRV2

162 odel of acute respiratory distress syndrome, lipid mediator metabololipidomics uncovered MaR1 generat

163 In this study, using lipid mediator metabololipidomics with murine joints we

164 itonitis and resolution indices coupled with lipid mediator metabololipidomics, we found that aged mi

165 hromatography-tandem mass spectrometry-based lipid mediator metabololipidomics, we found that PCTR1 i

166 coupled with tandem mass spectrometry-based lipid-mediator metabololipidomics to identify and quanti

167 Lipid mediator-metabololipidomics identified RvD1 and Rv

168 Targeted lipid mediator-metabololipidomics showed that both group

169 ololipidomics to identify and quantify three lipid-mediator metabolomes in basal peritoneal and zymos

170 Self-resolving inflammatory exudates and lipid mediator metabolomics recently uncovered a new fam

171 sting that supplementation with proresolving lipid mediators might reduce the development of emphysem

172 t C-1-P may function as an anti-inflammatory lipid mediator of immune response.

173 et (UV)-irradiated keratinocytes secrete the lipid mediator of inflammation, platelet-activating fact

174 s well as the immune-suppressive function of lipid mediators of inflammation and alarmins, are just s

175 synthesis of eicosanoids and other bioactive lipid mediators of inflammation and resolution underlyin

176 Lipid mediators of inflammation resolution, e.g., resolv

177 egulated metabolites mapping to pathways for lipid mediators of inflammation.

178 ucturally similar, but functionally distinct lipid mediators of inflammation.

179 helial migration; and metabolic programs for lipid mediators of lymphocyte motility and chemotaxis.

180 cid, and its metabolites, LTD4 and LTE4, are lipid mediators of smooth muscle constriction and inflam

181 hat the AF concentrations of proinflammatory lipid mediators of the 5-lipoxygenase pathway are signif

182 ammalian biology in the generation of potent lipid mediators of the inflammatory response; consequent

183 Endocannabinoids are lipid mediators of the same cannabinoid (CB) receptors t

184 Resolvins (Rv), which are highly potent lipid mediators, offer a viable alternative for better t

185 ificant benefits of specialized proresolving lipid mediators on survival and wound healing after majo

186 substrate, produced specialized proresolving lipid mediators, particularly D-series resolvins, which

187 lipid mediators and their relation to other lipid mediator pathways in humans after trauma.

188 poor outcomes after trauma have dysregulated lipid mediator pathways.

189 lecular studies have revealed that the local lipid mediator PGE2 is involved both in water excretion

190 C motif) ligand 1 (CXCL1, synonym KC) or the lipid mediator platetelet-activating factor (PAF) was on

191 cell-derived molecules such as cytokines and lipid mediators play a critical role in inducing chronic

192 Bioactive lipid mediators play a crucial role in the induction and

193 These data suggest that lipid mediators play a role in the regulation of autopha

194 Lipid mediators play an important role in reproductive b

195 owing appreciation of the diverse roles that lipid mediators play in modulating inflammatory response

196 atheroprogression, suggesting that resolving lipid mediators potentially represent an innovative stra

197 poxydocosapentaenoic acids (EDPs), which are lipid mediators produced by cytochrome P450 epoxygenases

198 Epoxyeicosatrienoic acids (EETs), lipid mediators produced by cytochrome P450 epoxygenases

199 d epidermal fatty acids was reflected in the lipid mediators produced, whereas similarities between l

200 reasons behind the aspirin-induced shift in lipid mediator production.

201 otomy resulted in an inflammatory peritoneal lipid mediator profile characterized by reduced concentr

202 Divergent shifts in lipid mediator profile following supplementation with n-

203 d EPA have highly divergent effects on human lipid mediator profile, with no overlap in PUFA metaboli

204 These results provide peripheral blood lipid mediator profiles in sepsis that correlate with su

205 Aortic lipid mediator profiling of aortas from Apoe(-/-) mice f

206 Herein, using lipid mediator profiling we identified MCTR in human ser

207 on days 3 and 7 thereafter and subjected to lipid mediator profiling.

208 Lipoxins, which are endogenously produced lipid mediators, promote the resolution of inflammation,

209 otal brake on fibroblast activation, and the lipid mediator prostaglandin E(2) (PGE(2)) exerts its we

210 The bioactive lipid mediator prostaglandin E(2) (PGE(2)) has been show

211 The endogenous lipid mediator prostaglandin E2 (PGE2) exerts anti-fibro

212 arensis to induce the synthesis of the small lipid mediator prostaglandin E2 (PGE2), which alters the

213 phenotype associated with production of the lipid mediator prostaglandin E2 (PGE2).

214 responsible for the formation of the potent lipid mediator prostaglandin E2 under proinflammatory co

215 These bioactive pro-resolving lipid mediators provide further rationale for the benefi

216 fts between proinflammatory and proresolving lipid mediators provides a link between metabolic and ce

217 tentially widely used mechanism in which key lipid mediators regulate microneme exocytosis.

218 tional functions have been proposed, notably lipid mediator release and a role in aspirin resistance.

219 emerin and the eicosapentaenoic acid-derived lipid mediator resolvin E1 (RvE1).

220 investigated the actions of two proresolving lipid mediators, resolvin D1 (RvD1) and resolvin D5 (RvD

221 E2, and a concomitant decrease of resolving lipid mediators, Resolvin D2 (RvD2) and Maresin 1 (MaR1)

222 tudies have demonstrated that the endogenous lipid mediators resolvins (RvE1 and RvD1), derived from

223 Analyses of lipid mediators revealed increased arachidonic acid and

224 ion through the release of a soluble, labile lipid mediator(s) that signals through the G(0)/G(i) rec

225 Through its metabolism of the EETs and other lipid mediators, sEH contributes to the regulation of va

226 nvolved in the production of proinflammatory lipid mediators showed that 11q-deleted neuroblastoma tu

227 e potential for pharmacological targeting of lipid mediator signaling cascades in the treatment of in

228 ially if endogenous specialized proresolving lipid mediator signaling is impaired.

229 Fatty acids and lipid mediator signaling play an important role in the p

230 ose that spatial compartmentalization of the lipid mediator sphingosine 1-phosphate (S1P) may be one

231 ultiphoton microscopy, we show here that the lipid mediator sphingosine 1-phosphate (S1P) serves as a

232 Here, we determined that provision of the lipid mediator sphingosine 1-phosphate (S1P) to the syst

233 Serum levels of the lipid mediator sphingosine-1-phosphate (S1P) are reduced

234 ometry to identify specialized pro-resolving lipid mediators (SPM) in histologically-defined stable a

235 ess orchestrated by specialized proresolving lipid mediators (SPM) that limit the host response withi

236 is, and temporally regulates local levels of lipid mediator/SPM.

237 n of the downstream specialized proresolving lipid mediators (SPMs) 14-hydroxydocosahexaenoic acid, 1

238 Specialized proresolving lipid mediators (SPMs) are endogenous autacoids that act

239 cterized effects of specialized proresolving lipid mediators (SPMs) derived from eicosapentaenoic aci

240 ocess that involves specialized proresolving lipid mediators (SPMs) derived from n-3 (omega-3) fatty

241 Specialized proresolving lipid mediators (SPMs) derived from omega-3 polyunsatura

242 dence suggests that specialized proresolving lipid mediators (SPMs) generated from docosahexaenoic ac

243 Ns]), production of specialized proresolving lipid mediators (SPMs), generation of specific growth fa

244 rom a lack of local specialized proresolving lipid mediators (SPMs), such as resolvins and protectins

245 ess orchestrated by specialized proresolving lipid mediators (SPMs).

246 Because specialized proresolving lipid mediators (SPMs; lipoxins, resolvins, and protecti

247 ressful, induced a higher production of some lipid mediators such as hydroperoxides and EPA-derived p

248 migration is mediated by both chemokines and lipid mediators such as leukotrienes and prostaglandins,

249 Other lipid mediators such as nitrosylated-fatty acids and ome

250 growth factor-beta family, and proresolving lipid mediators (such as lipoxins, resolvins, and protec

251 at PAR(2) generates arachidonic acid-derived lipid mediators, such as 5',6'-EET, that activate TRPV4.

252 inflammation; however, it is unclear whether lipid mediators, such as cysteinyl leukotrienes (CysLTs)

253 res biosynthesis of specialized proresolving lipid mediators, such as E-series resolvin (RvE) 1, and

254 testine, it causes the formation of anorexic lipid mediators, such as oleoylethanolamide, which promo

255 The resolution process is regulated by lipid mediators, such as those derived from the omega-3

256 The perturbations of lipid mediators suggested that PFOS has potential negati

257 therapy did not affect circulating levels of lipid mediators, suggesting that pleiotropic effects are

258 This lipid mediator switch represents a novel mechanism of Ox

259 at H1N1 induces surface receptor activation, lipid mediator synthesis, and release of microparticles

260 5 PUFAs, covering pro and anti-inflammatory lipid mediators synthesized across the cyclooxygenase (C

261 Prostaglandin E(2) (PGE(2)) is a lipid mediator that acts by ligating 4 distinct G protei

262 Lysophosphatidic acid (LPA) is a lipid mediator that functions as a mitogen by acting thr

263 Platelet-activating factor (PAF) is a potent lipid mediator that has been implicated in endotoxin-ass

264 Prostaglandin E2 (PGE2) is a pleiotropic lipid mediator that is synthesized from arachidonic acid

265 Prostaglandin E2 (PGE2) is a potent lipid mediator that plays a key role in inflammation and

266 ligand for 5 specific receptors, is a potent lipid mediator that plays important roles in lymphocyte

267 1-phosphate (S1P) is a pleiotropic bioactive lipid mediator that promotes breast cancer progression b

268 hormones and prostaglandin D(2) (PGD(2)), a lipid mediator that promotes skin inflammation in atopic

269 dic acid (LPA) is a highly potent endogenous lipid mediator that protects and rescues cells from prog

270 Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator that regulates many processes in inflamma

271 o sphingosine-1-phosphate (S1P), a bioactive lipid mediator that regulates many processes in vertebra

272 They are lipid mediators that act as autocrine or paracrine facto

273 The lipoxins LXA4 and LXB4 are small lipid mediators that act locally to dampen inflammation,

274 n and are a rich source of newly synthesized lipid mediators that alter vascular permeability and smo

275 eukotrienes (cysLTs) are bronchoconstricting lipid mediators that amplify eosinophilic airway inflamm

276 Prostaglandins are lipid mediators that are involved in a plethora of biolo

277 ase proinflammatory chemokine, cytokine, and lipid mediators that attract further neutrophils and mon

278 entenone prostaglandins (cyPGs) are reactive lipid mediators that bind covalently to proteins and exe

279 Phospholipase A2s generate lipid mediators that constitute an important component o

280 Leukotrienes are proinflammatory lipid mediators that have been shown to be upregulated i

281 have uncovered a new genus of pro-resolving lipid mediators that include the lipoxin, resolvin, prot

282 Lipoxins (LX) are proresolution lipid mediators that inhibit phlogistic neutrophil recru

283 f the D-series are specialized pro-resolving lipid mediators that regulate cellular response by orche

284 1 enzymes to the local metabolite profile of lipid mediators that regulate neutrophilic inflammation.

285 esized that CGI-58 is involved in generating lipid mediators that regulate TAG metabolism and insulin

286 and oleoylethanolamide (OEA) are endogenous lipid mediators that suppress inflammation.

287 mediators, called "specialized proresolving lipid mediators," that includes resolvin D1 (RvD1).

288 on the CYP450 family of epoxygenases and the lipid mediators they produce.

289 t al. highlight yet another function of this lipid mediator: thrombopoiesis.

290 of numerous molecules, from antioxidants and lipid mediators to growth factors, cytokines, and chemok

291 Lipid mediators variedly affect adipocyte differentiatio

292 Following zymosan-initiated inflammation, 18 lipid mediators were identified, including members of th

293 levels of n-3 and n-6 PUFA-derived bioactive lipid mediators were quantified by an unbiased liquid ch

294 lamide (anandamide), a major endocannabinoid lipid mediator, were more susceptible to PTB upon lipopo

295 ve regulates both netrin-1 and pro-resolving lipid mediators, which act in a bidirectional fashion to

296 Herein we discuss a novel class of bioactive lipid mediators, which are enzymatically biosynthesized

297 Our results document the existence of novel lipid mediators, which are involved in the beneficial an

298 Leukotriene B4 is a proinflammatory lipid mediator whose role in peripheral nociceptive sens

299 Lipoxin A4 (LXA4) is an endogenous lipid mediator with potent anti-inflammatory properties

300 4 (LTC4), LTD4, and LTE4 are proinflammatory lipid mediators with pathobiologic function in asthma.